Demonstrates potent inhibition of TLR7 and TLR9 in mouse models, suggesting therapeutic potential for autoimmune diseases.
, demonstrated robust dose-dependent inhibition of TLR7 and TLR9 pathways in mouse challenging models, supporting the potential of a TLR7/8/9 triple antagonist for treating autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: